Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

814 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Thigpen JT, et al. Among authors: markman m. Gynecol Oncol. 2005 Jan;96(1):10-8. doi: 10.1016/j.ygyno.2004.09.046. Gynecol Oncol. 2005. PMID: 15589573 Review.
Ovarian cancer.
Hennessy BT, Coleman RL, Markman M. Hennessy BT, et al. Among authors: markman m. Lancet. 2009 Oct 17;374(9698):1371-82. doi: 10.1016/S0140-6736(09)61338-6. Epub 2009 Sep 28. Lancet. 2009. PMID: 19793610
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS. Pitiyarachchi O, et al. Among authors: markman m. Gynecol Oncol. 2022 Sep;166(3):410-416. doi: 10.1016/j.ygyno.2022.07.004. Epub 2022 Jul 11. Gynecol Oncol. 2022. PMID: 35835612 Free PMC article.
Emerging therapeutics for primary peritoneal cancer.
Slomovitz BM, Worley MJ, Markman M, Coleman RL. Slomovitz BM, et al. Among authors: markman m. Expert Opin Emerg Drugs. 2011 Mar;16(1):71-84. doi: 10.1517/14728214.2011.526600. Expert Opin Emerg Drugs. 2011. PMID: 21352070 Review.
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB. Fu S, et al. Among authors: markman m. Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6. Gynecol Oncol. 2012. PMID: 22487539 Free PMC article. Clinical Trial.
ICON3 and chemotherapy for ovarian cancer.
Ozols RF, Markman M, Thigpen JT. Ozols RF, et al. Among authors: markman m. Lancet. 2002 Dec 21-28;360(9350):2086-7; author reply 2088. doi: 10.1016/S0140-6736(02)11984-2. Lancet. 2002. PMID: 12504453 No abstract available.
814 results